Selenium and the course of mild Graves' orbitopathy

New England Journal of Medicine

Volumn 364, Issue 20, 2011, Pages 1920-1931

  Marcocci, Claudio ^a   Kahaly, George J ^c   Krassas, Gerasimos E ^d   Bartalena, Luigi ^b   Prummel, Mark ^f   Stahl, Matthias ^g   Altea, Maria Antonietta ^a   Nardi, Marco ^a   Pitz, Susanne ^b   Boboridis, Kostas ^e   Sivelli, Paolo ^c   Von Arx, George ^h   Mourits, Maarten P ^f   Baldeschi, Lelio ^f   Bencivelli, Walter ^a   Wiersinga, Wilmar ^f  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d PANAGIA GENERAL HOSPITAL   (Greece)

^e AHEPA UNIVERSITY HOSPITAL   (Greece)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g KANTONSSPITAL   (Switzerland)

^h Admedico Augenzentrum Olten   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PLACEBO; SELENIUM;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOATING; CLINICAL ACTIVITY SCORE; CONTROLLED STUDY; DIPLOPIA SCORE; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; ERYTHEMA; EYE EXAMINATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 79956208355     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1012985     Document Type: Article

References (35)

1. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000;21:168-99. (Pubitemid 32275594)
2. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158:273-85. (Pubitemid 351404990)
3. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid 1997;7:885-9. (Pubitemid 28041663)
4. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998;82:773-9. (Pubitemid 28376907)
5. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995;42:45-50.
6. Rayman MP. The importance of selenium to human health. Lancet 2000;356:233-41. (Pubitemid 30446984)
7. Burch HB, Lahiri S, Bahn RS, Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy. Exp Eye Res 1997;65:311-6. (Pubitemid 27360161)
8. Heufelder AE, Wenzel BE, Bahn RS. Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves' retroocular fibroblasts. J Clin Endocrinol Metab 1992;74:737-42.
9. Lu R, Wang P, Wartofsky L, et al. Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. Thyroid 1999;9:297-303. (Pubitemid 29171781)
10. Hoffmann PR, Berry MJ. The influence of selenium on immune responses. Mol Nutr Food Res 2008;52:1273-80.
11. Negro R. Selenium and thyroid autoimmunity. Biologics 2008;2:265-73.
12. Nacamulli D, Mian C, Petricca D, et al. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol (Oxf) 2010;73:535-9.
13. Vrca VB, Skreb F, Cepelak I, Romic Z, Mayer L. Supplementation with antioxidants in the treatment of Graves' disease: the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta 2004;341:55-63. (Pubitemid 38210314)
14. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999;159:337-45. (Pubitemid 29091621)
15. Anaya JM, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J Rheumatol 1995;22:595-9.
16. Dezube BJ, Sherman ML, Friedovich-Keil JL, Allen-Ryan J, Pardee AB. Downregulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993;36:57-60.
17. Okunieff P, Augustine E, Hicks JE, et al. Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol 2004;22:2207-13. (Pubitemid 41095157)
18. Chang CC, Chang TC, Kao SC, Kuo YF, Chien LF. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial myxoedema. Acta Endocrinol (Copenh) 1993;129:322-7. (Pubitemid 23319224)
19. Balazs C, Kiss H, Farid NR. Inhibitory effect of pentoxifylline on HLA-DR expression and glycosaminoglycan synthesis by retrobulbar fibroblasts. Horm Metab Res 1998;30:496-9. (Pubitemid 28420068)
20. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003;24:802-35. (Pubitemid 38067700)
21. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726-38.
22. Balazs C, Kiss E, Vamos A, Molnar I, Farid NR. Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO): a pilot study. J Clin Endocrinol Metab 1997;82:1999-2002. [Erratum, J Clin Endocrinol Metab 1997;82:3077.]
23. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001;55:283-303. (Pubitemid 32823038)
24. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47:9-14. [Erratum, Clin Endocrinol (Oxf) 1997;47:632.]
25. Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 1987;16:391-407. (Pubitemid 18088083)
26. Terwee CB, Dekker FW, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf) 2001;54:391-8. (Pubitemid 32234205)
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
28. Abalovich M, Llesuy S, Gutierrez S, Repetto M. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol (Oxf) 2003;59:321-7. (Pubitemid 37046985)
29. Ademoǧlu E, Ozbey N, Erbil Y, et al. Determination of oxidative stress in thyroid tissue and plasma of patients with Graves' disease. Eur J Intern Med 2006;17:545-50. (Pubitemid 44827700)
30. Dehina NE, Minich W, Behrends T, Morgenthaler NG, Kohrle J, Schomburg L. Circulating selenoprotein P concentrations are decreased in patients with Graves' disease and correlate inversely to severity of orbitopathy. Acta Med Port 2009;22:1.
31. Krassas G, Karras S, Boboridis K, Spanos E. Selenium serum levels in patients with mild Graves' orbitopathy: results of a controlled study. Presented at the 12th European Congress of Endocrinology, Prague, Czech Republic, April 24-28, 2010. abstract.
32. Wertenbruch T, Willenberg HS, Sagert C, et al. Serum selenium levels in patients with remission and relapse of Graves' disease. Med Chem 2007;3:281-4. (Pubitemid 46773944)
33. Bouzas EA, Karadimas P, Mastorakos G, Koutras DA. Antioxidant agents in the treatment of Graves' ophthalmopathy. Am J Ophthalmol 2000;129:618-22. (Pubitemid 30323727)
34. Rayman MP. Food-chain selenium and human health: emphasis on intake. Br J Nutr 2008;100:254-68.
35. Burney P, Potts J, Makowska J, et al. A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project. Allergy 2008;63:865-71. [Erratum, Allergy 2008;63:1647.]